Table 3.

Circulation-related complications of COVID-19 encountered by the acute respiratory disease support team

PathologyMain learning to consider
Right ventricular dysfunction and pulmonary hypertensionSuccessful use of sildenafil to improve pulmonary haemodynamics
Normalised in 90% patients at 3 months; Sildenafil subsequently discontinued
Pulmonary thromboembolic diseaseIn situ thrombosis: resolved at 3 months
Pulmonary emboli: risk of CTEPH; VQ scan can be useful
Atrial fibrillationDigoxin used as preferred drug for rate control because of risk of bronchospasm and ILD associated with beta-blockers and amiodarone, respectively
  • COVID-19 = Coronavirus disease 2019; CTEPH = chronic thromboembolic pulmonary hypertension; ILD = interstitial lung disease; VQ scan = ventilation–perfusion scan.